1. Antibody-drug Conjugate/ADC Related
  2. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. ADCs are complex molecules composed of an antibody linked, via a stable, chemical, linker with labile bonds, to a biological active cytotoxic (anticancer) payload or drug. By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. This means that, in contrast to traditional chemotherapeutic agents, antibody-drug conjugates target and attack the cancer cell so that healthy cells are less severely affected.

Drug-Linker Conjugates for ADC Related Products (17):

Cat. No. Product Name Effect Purity
  • HY-15575
    VcMMAE 99.89%
    VcMMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
  • HY-19792
    Mertansine 98.51%
    Mertansine is a tubulin inhibitor,inhibits the assemblyof microtubules by binding to tubulin, with a linker structure can create an antibody-drug conjugate (ADC).
  • HY-100374
    Val-Cit-PAB-MMAE 99.83%
    Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide Val-Cit-PAB.
  • HY-15578
    McMMAF >99.0%
    Mc-MMAF is a protective group-conjugated MMAF.
  • HY-100567
    MAL-di-EG-Val-Cit-PAB-MMAE 99.57%
    MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), MAL-di-EG-Val-Cit-PAB-MMAE is an antibody drug conjugate.
  • HY-12460
    SPDB-DM4
    SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4) via a SPDB linker, exhibiting potent anti-tumor activity.
  • HY-101141
    sulfo-SPDB-DM4
    sulfo-SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4) via the sulfo-SPDB linker.
  • HY-101070
    SMCC-DM1 99.54%
    SMCC-DM1 is DM1 with a reactive linker SMCC to make antibody drug conjugate.
  • HY-19812
    Acetylene-linker-Val-Cit-PABC-MMAE
    Acetylene-linker-Val-Cit-PABC-MMAE consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE), Acetylene-linker-Val-Cit-PABC-MMAE is an antibody drug conjugate.
  • HY-15741
    Mc-MMAE
    Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate (ADC).
  • HY-100566
    SuO-Val-Cit-PAB-MMAE
    SuO-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide SuO-Val-Cit-PAB.
  • HY-100874
    N3-PEG3-vc-PAB-MMAE 99.18%
    N3-PEG3-vc-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide N3-PEG3-vc-PAB.
  • HY-15740
    Mc-MMAD
    Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate; Mc-MMAD is a protective group (maleimidocaproyl) -conjugated MMAD.
  • HY-15750
    Cys-mcMMAD
    Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.
  • HY-19813
    mDPR-Val-Cit-PAB-MMAE
    mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.
  • HY-19811
    Fmoc-Val-Cit-PAB-MMAE
    Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), Fmoc-Val-Cit-PAB-MMAE is an antibody drug conjugate.
  • HY-15742
    Vc-MMAD
    Vc-MMAD consists the ADCs linker(Val-Cit) and potent tubulin inhibitor (MMAD), Vc-MMAD is an antibody drug conjugate.